RegeneRx Announces Positive Phase III Results for RGN-259 in Dry Eye

November 17, 2017: By Jon Swedien

RegeneRx Biopharmaceuticals’ proposed dry eye treatment, RGN-259, showed statistically significant improvement over placebo in its ARISE-2 Phase III clinical study, the Rockville, Maryland company reported Oct. 31.

RGN-259, a Thymosin beta 4 (Tβ4)-based sterile and preservative-free eye drop, is as a novel treatment candidate for dry eye and neurotrophic keratitis (NK), and other corneal diseases, RegeneRx said.

The ARISE-2 trial was sponsored by ReGenTree, a US joint venture company owned by GtreeBNT, a bio venture company in South Korea, and RegeneRx.

The trial investigated the safety and efficacy of RGN-259 for the treatment of the signs and symptoms of dry eye syndrome in 601 patients.

RGN-259 (0.1%) demonstrated a number of statistically significant improvements in both signs and symptoms, while showing excellent safety, comfort, and tolerability profiles, ReGenTree said.

For example, the RGN-259-treated group saw a statistically significant reduction in ocular discomfort at day 15 compared with placebo (p=0.0149) in a change from baseline, ReGenTree said.

ReGenTree president and CEO Won S. Yang said the company plans to meet with the US FDA to discuss the ARISE-2 findings.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT